/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
Valued at a market cap of $10.57 billion, Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. The Wilmington, Massachusetts-based company is known for its specialized expertise in drug discovery and development and its comprehensive portfolio of laboratory services.
Shares of this healthcare company have significantly underperformed the broader market over the past 52 weeks. CRL has gained 1.6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 27%. In 2024, shares of CRL are down 13.2%, compared to SPX’s 18.1% gains on a YTD basis.